Dr. Mary M. Klix, MD

Dr. Klix practices at Katmai Oncology Group in Anchorage, Alaska.

Dr. Klix's NPI, 1669447595, was assigned on February 22, 2006. Dr. Klix graduated from University of Missouri School of Medicine in 1997. Dr. Klix holds Missouri license 112773.

Dr. Klix's primary practice is Katmai Oncology Group, at 3851 Piper St, Anchorage, AK 99508 in Anchorage Borough. The practice phone is (907) 562-0321.

Dr. Klix's primary practice is Katmai Oncology Group in Anchorage, Alaska. Dr. Klix is also affiliated with Providence Alaska Medical Center. The medical group on file is Katmai Oncology Group. Dmand AI also links Dr. Klix to 1 more hospital and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Klix practices, 3 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Klix's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Klix is board certified in medical oncology by the American Board of Internal Medicine. Dmand AI has Dr. Klix's licenses on file in 3 states: Missouri, Alaska and Iowa.

Dmand AI lists breast cancer, chronic anemia, chronic leukemia, colorectal cancer, immune deficiency disease, lung cancer, lymphoma and multiple myeloma among the conditions Dr. Klix treats.

CMS data shows 2,843 Medicare services from Dr. Klix across 25 procedure codes in 2024, for 332 Medicare patients. Medicare paid $75,332 for them.

CMS counts 332 Medicare patients who saw Dr. Klix in 2024. The largest group is 65 to 74, with 164 patients. 70% of them have high blood pressure, and 57% have high cholesterol. 19% are also on Medicaid. Their average risk score is 1.75, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Klix's median patient age at 66, with 64% women.

In 2024, Dr. Klix wrote 370 Medicare Part D claims for 74 patients. 65% of them were for generic drugs. CMS names the drug for 177 of them, across 9 drugs with 11 or more claims each, at $947,730 in total drug cost. In 2023, CMS named 255 claims across 13 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 90 out of 100 for Dr. Klix for performance year 2024, reported as part of a group. Dr. Klix accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Klix as offering telehealth.

Dmand AI links 2 papers to Dr. Klix in 2020. Dr. Klix's most frequent co-authors are Edward P. Balaban, DO, Elizabeth M. Blanchard, MD and Linda Diana Bosserman, FACP, MD.

Dmand AI links Dr. Klix to 1 clinical trial. 1 is still active or recruiting. Conditions studied include Breast Neoplasms and Breast Diseases.

CMS Open Payments shows 555 general payments to Dr. Klix from 81 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 72% of the total. Pharmacyclics LLC, An AbbVie Company paid the most, $3,842.

Dr. Klix graduated from University of Missouri School of Medicine in 1997.

Dr. Klix is in network with 10 carriers, including Aetna, United Healthcare and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 6. Check the plan with the practice before a visit.